Simplify Logo

Full-Time

Senior Director

Computational Chemistry

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS cancers

Hardware
Biotechnology
Healthcare

Compensation Overview

$235k - $281kAnnually

+ Equity Awards + Cash Compensation + Benefits + Learning and Development Opportunities

Expert

San Carlos, CA, USA

Category
Computational Biology
Genomics
Biology & Biotech
Requirements
  • Ph.D. degree in a relevant scientific discipline with over 15+ years’ experience in the pharmaceutical/biotech industry alongside a strong track record of positive impact in programs
  • Expertise in a broad variety of computational techniques is essential, particularly molecular docking, pharmacophore development, library design and analysis, machine learning methods, and protein-protein/protein-ligand simulation
  • Experience in applying ML methods to garner new insights or drive program direction
  • Recognized as an intellectual leader in the early phases of drug discovery with a track record of patents, publications and project achievements
  • Demonstrates ability to recognize anomalous and inconsistent results and interpret experimental outcomes
  • Demonstrated ability to plan and achieve research goals as part of an interdisciplinary team
  • Knowledge of oncology therapeutic area and drug discovery
  • Excellent written and verbal communication skills to work with interdepartmental teams
  • Evidence of successful coaching, mentorship and development of both individuals and teams in order to build long-term organizational capability
Responsibilities
  • Guide the strategy for expanding the capabilities of structure based drug design within RevMed’s unique mode of action
  • Grow the capabilities and leverage modern ML methodology to improve the efficiency of our design cycle
  • Managing, coaching and mentoring scientists across the computational chemistry function in order to develop their skills and build RevMed’s organizational capabilities
  • Being a partner in the scientific activities of other outstanding scientists across Revolution Medicines and helping create an environment where we channel scientific curiosity to build and deliver a sustainable portfolio
  • Advancing the RevMed Research Portfolio and helping build our scientific reputation through presentation/publication of project results in scientific meetings and peer-reviewed literature, as guided by RevMed publication policies, to build our scientific reputation
  • Identifying, establishing and leading partnerships with selected strategic technology partners focused on supporting RevMed projects

Revolution Medicines develops targeted treatments for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main products are RASON Inhibitors, designed to inhibit the activity of RAS proteins that promote cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses specifically on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$1.3B

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

15%

1 year growth

40%

2 year growth

111%
Simplify Jobs

Simplify's Take

What believers are saying

  • The acquisition of EQRx is expected to add over $1 billion in net cash, significantly bolstering Revolution Medicines' financial position.
  • Successful public offerings and underwriters' full exercise of options have brought substantial capital, indicating strong investor confidence.
  • The company's innovative RASON Inhibitors and Tri Complex Inhibitor platform have the potential to revolutionize treatment for RAS-driven cancers, offering significant clinical impact.

What critics are saying

  • The highly specialized focus on RAS-driven cancers may limit market size and revenue potential compared to broader oncology companies.
  • Integration challenges from the acquisition of EQRx could divert focus and resources, potentially impacting ongoing projects.

What makes Revolution Medicines unique

  • Revolution Medicines focuses exclusively on RAS-driven cancers, a niche but critical area in oncology, unlike broader-spectrum oncology companies.
  • Their Tri Complex Inhibitor platform allows for highly specialized treatments, setting them apart from competitors with more generalized approaches.
  • The company's revenue model, which includes licensing, co-development partnerships, and direct sales, provides multiple revenue streams, enhancing financial stability.